10 Hartom Street, 2nd Floor
P.O. Box 45182
Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to select, develop and ultimately commercialize oral medications that are currently only available as injections.
Founders: Guy Yachin, Muli Ben Sasson
CEO: Mark Leuctenberger
CFO: Mark Fitzpatrick
Please click here for Chiasma job opportunitites.
Please click here for clinical trial information.